Clinical trial
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and…
NCT00087698 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00087698 |
|---|---|
| Title | Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma |
| Official title | A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed (Alimta) Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pleural Neoplasms |
| Intervention type | Drug |
| Interventions | pemetrexed, cisplatin |
| Enrollment | 77 |
| Start date | Sep 1, 2003 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jul 16, 2004 |
| Last update posted | May 12, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: